Because of the properties of high GPNMB expression at the surface of cancer cells but significant expression intracellularly in normal cells, GPNMB-targeting monoclonal antibodies are promising candidates for the treatment of patients with GPNMB-expressing cancers [13]. This evidence concerns the gene GPNMB and cancer.